PPARA and metabolic dysfunction-associated steatotic liver disease: A recent study has found that the activation of the PI3K-Akt signaling pathway could inhibit the expression of SREBP1c and PPARα protein, finally resulting in lipid metabolism disorders and insulin resistance, promoting the process of NAFLD [29].